Plain-English translation of NCT07306832 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new medication called to treat children with acute myeloid leukemia (AML) — an aggressive blood cancer — that has either returned after treatment or stopped responding to previous drugs. Researchers want to understand how safe this medication is and how the body processes it. About 18 children ages 6 months to 17 years will participate at hospitals around the world.
Children with AML that comes back or doesn't respond to standard treatments have very few options left. This medication is being studied because early research suggests it may help children in this difficult situation.
You likely qualify if…
You likely don't qualify if…
If your child is enrolled, they will receive the new medication through an IV (intravenous line) as the main treatment. The study lasts about 28 months, and your family will attend regular clinic visits for blood tests, health check-ups, and monitoring for any side effects. Your child will be placed in one of three age groups, and the medication dose will be based on their weight.
AI-generated summary from trial data · Jul 22, 2026 · Not medical advice
United States
Australia
Italy